Lakewood-Amedex Biotherapeutics IncLABT
Price$0.93

Outlook & Key Dates

Estimates, guidance, catalysts, and upcoming events

Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
As of 18 Aug 2026
FY EPS (est.)
-$2.52next fiscal year
As of 18 Aug 2026
Monitoring Framework
Key Performance Indicators
Phase 2a Clinical Trial Initiation for Nu-3 Gel QuarterlyTarget: Initiation of patient dosing in Phase 2a safety and dose-response trial
Cash and Cash Equivalents Quarterly11.7KTarget: Sufficient capital to fund Phase 2a clinical operations
Watch Items
  • Phase 2a clinical trial enrollment and safety data for Nu-3 Gel in mildly infected diabetic foot ulcers (iDFU)Trigger: Completion of Phase 2a dose selection (2%, 5%, and 10% gel concentrations)Action: Review safety profile and prepare for the subsequent placebo-controlled Phase 2b study
  • Liquidity and capital runwayTrigger: Cash burn exceeding available reserves from the April 2026 Series C Preferred Stock private placementAction: Evaluate additional dilutive or non-dilutive financing options, including partnerships or debt
Sign in / Sign up to read more

Research as of 24 Jul 2026

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.